welcome
Investor's Business Daily

Investor's Business Daily

Business

Business & Economics

Gilead Sciences stock slides on reports federal funding for HIV prevention could be cut

Investor's Business Daily
Summary
Nutrition label

71% Informative

Gilead Sciences' HIV treatments accounted for 68% of its revenue last year .

Last year , the company generated north of $19.61 billion in sales of its HIV treatments.

The company doesn't separate out which sales came from pre-exposure prophylaxis, or PrEP.

VR Score

69

Informative language

69

Neutral language

57

Article tone

formal

Language

English

Language complexity

28

Offensive language

possibly offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links